Inclusion Criteria:  Agree to participate in the trial by signing the IRB approved Informed Consent Age ≥ 18 years of age Positive diagnosis for COVID-19 by SARS-CoV-2 PCR by nasopharyngeal swab within the past 3 days Two or more COVID-19 symptoms (at least one of which must be Respiratory) rated Mild or Moderate on the COVID-19 adapted FLU-PRO Plus scale SpO2 ≥ 94% Ambulatory (not hospitalized) at the time of enrollment  At increased risk of developing more severe COVID-19 disease (at least one of the following):  Age ≥60 years Presence of pulmonary disease, specifically moderate or severe persistent asthma, chronic obstructive pulmonary disease, pulmonary hypertension, emphysema Diabetes mellitus (type 1 or 2), requiring oral medication or insulin for treatment Cardiovascular disease, including Hypertension, requiring at least 1 oral medication for treatment; congestive heart failure; coronary artery disease; cardiomyopathy; pulmonary hypertension Body mass index ≥30 Chronic renal disease (but not on dialysis) Sickle cell disease or trait Comorbid disease (as above) well controlled/stable in opinion of the Investigator Normal (or stable if abnormal per comorbidity) baseline ECG Men of child-bearing potential must use birth control with heterosexual partner(s) (abstinence or condoms)  Women of child-bearing potential must meet all the following criteria:  Use of birth control (abstinence, oral contraceptives, condoms, or intrauterine device) Test negative for β-subunit of HCG  Exclusion Criteria:  Pregnant or lactating Treatment with COVID-19 antiviral such as remdesivir or SARS-CoV-2 antibodies Prior COVID-19 vaccination or prior recovery from documented COVID-19 infection Severe or Critical COVID-19, as indicated by respiratory distress or shortness of breath at rest; Resp Rate ≥30/min; Heart rate ≥125/min; SpO2 ≤ 93% on room air or PaO2/FiO2 ≤ 300 if on supplemental O2 Positive HIV or positive Hepatitis Panel Treatment with any medications known to be strongly metabolized by CYP3A4 or CYP2D6